1. Age-adjusted Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiation therapy.
- Author
-
Tanaka H, Takenaka Y, Nakahara S, Hanamoto A, Fukusumi T, Michiba T, Takemoto N, Cho H, Yamamoto M, Yamamoto Y, and Inohara H
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell mortality, Cause of Death, Comorbidity, Female, Humans, Hypopharyngeal Neoplasms diagnosis, Hypopharyngeal Neoplasms mortality, Japan epidemiology, Male, Middle Aged, Prognosis, Retrospective Studies, Carcinoma, Squamous Cell therapy, Hypopharyngeal Neoplasms therapy
- Abstract
Conclusion: The age-adjusted Charlson comorbidity index (ACCI) was associated with overall survival, disease-specific survival, and non-cancer death in patients treated with chemoradiation therapy (CRT) for hypopharyngeal cancer (HPC). Further studies using other CRT regimens are required., Objective: To investigate the impact of the ACCI on survival in patients with HPC., Methods: This study reviewed 128 patients with HPC who received CRT between 2004-2012. The survival rates and the cumulative incidence of non-cancer death according to the ACCI were estimated. A Cox proportional hazard model was used to assess the hazard ratio (HR) of the ACCI., Results: The disease-specific survival rates at 3 years for the low ACCI group, moderate group, and high group were 80.1%, 45.8%, and 54.8%, respectively (p = 0.007). The laryngectomy-free survival rates at 3 years were 61%, 39.7%, and 37.1%, respectively (p = 0.137). The cumulative incidences of non-HPC death were 5% for the low/moderate ACCI group and 15.5% for the high ACCI group (p = 0.031). The HRs compared to the low ACCI group for overall survival, disease-specific survival, and laryngectomy-free survival were 2.61 and 2.74, 2.55 and 2.27, and 1.75 and 1.97 in the moderate and high ACCI groups, respectively.
- Published
- 2017
- Full Text
- View/download PDF